What is BofA Securities's price target for RYTM?

BofA Securities's latest stated price target for Rhythm Pharmaceuticals Inc. (RYTM) is $63, from its action on Apr 7, 2025.

What is BofA Securities's rating on RYTM?

BofA Securities rates RYTM Buy, a bullish rating, as of Apr 7, 2025.

When did BofA Securities last change its view on RYTM?

On Apr 7, 2025, BofA Securities upgrades to Buy from Neutral, price target $63.

Analyst firms · BofA Securities · RYTM

BofA Securities RYTM price target and rating history

Rhythm Pharmaceuticals Inc. (RYTM) · Health Care

BofA Securities rates Rhythm Pharmaceuticals Inc. (RYTM) Buy with a $63 price target, as of its latest action on Apr 7, 2025. It has published 5 rating actions on RYTM since August 2021, including 3 upgrades and 2 downgrades. Across 4 firms with a RYTM price target in the last 12 months, the median target is $134.50.

Current rating: Buy
Price target: $63
Median target, all firms: $134.50
Actions on RYTM: 5

BofA Securities price target on RYTM

BofA Securities price target on RYTM, each point a stated target, August 2021 to April 2025.

Every BofA Securities rating on RYTM

Apr 7, 2025
UpgradeBofA Securities upgrades to Buy from Neutral, price target $63
May 8, 2024
DowngradeBofA Securities downgrades to Neutral from Buy, price target $49 to $42
Aug 1, 2023
UpgradeBofA Securities upgrades to Buy from Neutral, price target $22 to $27
Aug 5, 2022
UpgradeBofA Securities upgrades to Neutral from Underperform, price target $8 to $20
Aug 4, 2021
DowngradeBofA Securities downgrades to Underperform from Neutral, price target $33 to $17

How other firms rate RYTM

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
William Blair	Outperform		Oct 16, 2026
Wolfe Research	Outperform		Sep 17, 2026
Leerink Partners	Outperform	$133	Sep 14, 2026
Deutsche Bank	Hold	$120	Aug 28, 2026
RBC Capital Markets	Outperform	$478	Feb 19, 2026
Citigroup	Buy	$136	Nov 25, 2025

Questions about BofA Securities and RYTM

What is BofA Securities's price target for RYTM?: BofA Securities's latest stated price target for Rhythm Pharmaceuticals Inc. (RYTM) is $63, from its action on Apr 7, 2025.
What is BofA Securities's rating on RYTM?: BofA Securities rates RYTM Buy, a bullish rating, as of Apr 7, 2025.
When did BofA Securities last change its view on RYTM?: On Apr 7, 2025, BofA Securities upgrades to Buy from Neutral, price target $63.
How does BofA Securities's RYTM target compare with other analysts?: Across 4 firms with a RYTM price target in the last 12 months, the median target is $134.50.

More RYTM rating histories

All BofA Securities ratings RYTM news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.